This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute lymphoblastic leukemia (ALL)	Potassium channel Kv11.1 (KCNH2)	Studies in mice and in patient samples suggest that inhibiting KCNH2 could help treat ALL. Bone marrow samples from ALL patients had greater KCNH2 surface expression than marrow from healthy controls. In a mouse model of ALL, a KCNH2 inhibitor decreased leukemic cell infiltration and increased survival compared with no treatment. Next steps include developing additional KCNH2 inhibitors.	Patent status undisclosed; available for licensing	Pillozzi, S. <i>et al. Blood</i> ; published online Nov. 3, 2010; doi:10.1182/blood-2010-01-262691 Contact: Annarosa Arcangeli, University of Florence, Florence, Italy e-mail: annarosa.arcangeli@unifi.it
<i>SciBX</i> 3(47); doi:10.1038/scibx.2010.1404 Published online Dec. 9, 2010				